featured
Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Diabetes Care
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials
Diabetes Care 2022 Apr 26;[EPub Ahead of Print], KR Tuttle, A Levin, M Nangaku, T Kadowaki, R Agarwal, SJ Hauske, A Elsäßer, I Ritter, D Steubl, C Wanner, DC WheelerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.